Search

Haemonetics Corp

Closed

SectorHealthcare

84.99 -1.61

Overview

Share price change

24h

Current

Min

85.4

Max

88.27

Key metrics

By Trading Economics

Income

-65M

-20M

Sales

7.4M

346M

P/E

Sector Avg

38.418

64.641

EPS

1.29

Profit margin

-5.817

Employees

3,009

EBITDA

-91M

4.3M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-5.81% downside

Dividends

By Acuity

Next Earnings

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

3.6B

Previous open

86.6

Previous close

84.99

News Sentiment

By Acuity

45%

55%

141 / 340 Healthcare

Haemonetics Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 19:56 UTC

Haemonetics Corp shares are higher, reflecting broader market gains amid positive momentum in major tech stocks and easing geopolitical tensions.

31 Jul 2026, 20:04 UTC

Haemonetics Corp shares are higher, with no specific news identified. The broader market has also gained since Thursday's close, recovering from earlier losses.

30 Jul 2026, 19:48 UTC

Haemonetics Corp. shares are lower today, continuing a decline since Wednesday. The stock remains above its 20-day moving average despite recent downward movement.

29 Jul 2026, 21:21 UTC

Haemonetics Corp shares are lower in after-market trading, reflecting broader declines in the equity market and Health Care Supplies sector amid rising oil prices.

28 Jul 2026, 21:01 UTC

Haemonetics Corp shares are lower in after-market hours, following a broader market decline amid a significant drop in the Nikkei 225 Index.

27 Jul 2026, 22:51 UTC

Haemonetics Corp shares are higher in after-market trading, supported by falling crude oil prices and strong performance above the 20-day moving average.

24 Jul 2026, 20:31 UTC

Haemonetics Corp shares are lower in after-market hours, continuing a decline from Friday's close. No specific news was identified to explain the movement.

23 Jul 2026, 23:21 UTC

Haemonetics Corp shares are lower in after-market trading, continuing a decline that began after Thursday's close, reaching the midpoint of their one-month trading range.

22 Jul 2026, 20:13 UTC

Shares of Haemonetics Corp are trading higher in after-market hours, positioned above its 20-day moving average amid broader market volatility and rising crude oil prices.

20 Jul 2026, 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Peer Comparison

Price change

Haemonetics Corp Forecast

Price Target

By TipRanks

-5.81% downside

12 Months Forecast

Average 80.57 USD  -5.81%

High 93 USD

Low 62 USD

Based on 9 Wall Street analysts offering 12 month price targets forHaemonetics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Sentiment

By Acuity

141 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
help-icon Live chat